title: Serum cytokeratin-19 measured by cyfra21-1 assay in patients with gastrointestinal and gynecologic malignancy.
abstract: The serum fragment of cytokeratin 19 was measured in 130 patients with gastrointestinal, breast and gynecologic cancer and 62 patients with benign disease using CYFRA21-1 immunoradiometric assay. Patients with advanced cancer showed the highest level of serum CYFRA21-1. When the cut-off level was set at 2 ng/ml, 7 of 61 patients with earlier stage cancer were positive whereas 45 of 69 patients with advanced cancer had serum CYFRA21-1 levels over 2 ng/ml. In benign gastrointestinal and gynecologic diseases, 4 of 66 patients were positive. Retrospective evaluation revealed a good correlation between the serum CYFRA21-1 concentration and clinical course. CYFRA21-1 may be a useful tumor marker for monitoring of gastrointestinal and gynecologic malignancies.
authors.affiliation: KYOTO UNIV HOSP,DEPT SURG,SAKYO KU,KYOTO 60601,JAPAN. KYOTO UNIV HOSP,DEPT OBSTET & GYNECOL,SAKYO KU,KYOTO 60601,JAPAN.
authors.forename: H
authors.initials: H
authors.lastname: Sakahara
authors.forename: T
authors.initials: T
authors.lastname: Kousaka
authors.forename: H
authors.initials: H
authors.lastname: Kobayashi
authors.forename: Z
authors.initials: Z
authors.lastname: Yao
authors.forename: M
authors.initials: M
authors.lastname: Imamura
authors.forename: T
authors.initials: T
authors.lastname: Mori
authors.forename: J
authors.initials: J
authors.lastname: Konishi